Theodore Scott Nowicki MD
Pediatric Sarcoma Oncology, Pediatric Solid Tumor Oncology
Physician
Join to View Full Profile
200 UCLA Medical PlzSte 265Los Angeles, CA 90095
Phone+1 310-825-0867
Fax+1 310-206-4855
Dr. Nowicki is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Theodore Nowicki is a pediatric hematologist/oncologist in Los Angeles, CA and is affiliated with Ronald Reagan UCLA Medical Center. He received his medical degree from New York Medical College and has been in practice 4 years. He specializes in pediatric sarcoma oncology and pediatric solid tumor oncology.
Education & Training
UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Pediatric Hematology/Oncology, 2016 - 2019- UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Pediatrics, 2013 - 2016
New York Medical CollegeClass of 2013
Certifications & Licensure
CA State Medical License 2014 - 2026
American Board of Pediatrics Pediatrics- American Board of Pediatrics Pediatric Hematology-Oncology
Clinical Trials
- Genetically Engineered PBMC and PBSC Expressing NY-ESO-1 TCR After a Myeloablative Conditioning Regimen to Treat Patients With Advanced Cancer Start of enrollment: 2017 Jul 26
Roles: Contact, Principal Investigator
Publications & Presentations
PubMed
- 1 citationsSelpercatinib prior to radioactive iodine for pediatric papillary thyroid carcinoma.Harvey K Chiu, Theodore S Nowicki, Masha J Livhits, James X Wu, Noah Federman
Journal of Pediatric Endocrinology & Metabolism. 2024-11-26 - Hypophosphatemia Correction Reduces ICANS Incidence and Duration in CAR T-cell Therapy: A Pooled Clinical Trial Analysis.Jack Pengfei Tang, Penelope Lafeuille, Alexandru Socolov, Sheila S Diamond, Jacob Aptekar
Cancer Research Communications. 2024-10-01 - 2 citationsInfusion Product TNFα, Th2, and STAT3 Activities Are Associated with Clinical Responses to Transgenic T-cell Receptor Cell Therapy.Theodore S Nowicki, Cole W Peters, Crystal Quiros, Conner K Kidd, Moe Kawakami
Cancer Immunology Research. 2023-12-01
Journal Articles
- Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-cell PopulationsZeynep Eroglu, Iman Osman, Theodore S Nowicki, Antoni Ribas, Michael A Davies, Farbod Darvishian, Daniel Y Wang, Douglas B Johnson, Ravi K Amaravadi, Clinical Cancer Research
Press Mentions
Dr. Theodore Scott Nowicki Awarded $4.5M NCI Grant to Advance Next Generation of Cellular Immunotherapies for Solid TumorsMarch 17th, 2025
Dr. Theodore Scott Nowicki Secures $4.5M NCI Grant to Propel Next-Generation Cellular Immunotherapies for Solid TumorsMarch 17th, 2025
Case Report Highlights Promising Approach for Treating Pediatric Thyroid CancerFebruary 7th, 2025- Join now to see all
Grant Support
- TNF-alpha-"armed" TCR vectors to enhance adoptive cell therapy for solid tumorsUNIVERSITY OF CALIFORNIA LOS ANGELES2025–2030
- Functional epigenomics of transgenic cellular immunotherapies for cancerUNIVERSITY OF CALIFORNIA LOS ANGELES2021–2026
- Functional epigenomics of transgenic cellular immunotherapies for cancerUNIVERSITY OF CALIFORNIA LOS ANGELES2021–2026
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
